ストックスクリーナーアプリを入手
24.68
3.78%
0.90
アフターアワーズ：
24.68
前日終値:
$23.78
開ける：
$23.85
24時間の取引高:
1.98M
Relative Volume:
0.77
時価総額：
$3.12B
収益：
$715.22M
当期純損益:
$-250.10M
株価収益率:
-12.16
EPS:
-2.03
ネットキャッシュフロー:
$-205.58M
1週間 パフォーマンス:
+16.14%
1か月 パフォーマンス:
+29.89%
6か月 パフォーマンス:
+26.05%
1年 パフォーマンス:
-28.75%
1日の値動き範囲:
$23.69
$24.71
1週間の範囲:
$21.16
$24.71
52週間の値動き範囲:
$16.10
$35.70
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
名前
Apellis Pharmaceuticals Inc
セクター
電話
617-977-5700
住所
100 FIFTH AVENUE, WALTHAM, KY
APLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
24.68 | 3.01B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-06 | 開始されました | Wolfe Research | Peer Perform |
| 2025-10-15 | 開始されました | Wells Fargo | Overweight |
| 2025-09-26 | ダウングレード | Goldman | Neutral → Sell |
| 2025-05-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-05-09 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-17 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-21 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-16 | 開始されました | William Blair | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Neutral |
| 2024-02-05 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-02 | 開始されました | Mizuho | Neutral |
| 2023-10-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-15 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 繰り返されました | Citigroup | Buy |
| 2023-08-03 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-08-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-19 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-17 | 再開されました | Stifel | Buy |
| 2022-04-14 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-09-10 | 繰り返されました | Credit Suisse | Neutral |
| 2021-09-10 | 繰り返されました | Needham | Buy |
| 2021-09-10 | 繰り返されました | Oppenheimer | Outperform |
| 2021-09-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-08-19 | 開始されました | Jefferies | Buy |
| 2021-08-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2020-11-19 | 開始されました | Needham | Buy |
| 2020-09-01 | 開始されました | Stifel | Buy |
| 2020-07-20 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-04-01 | 開始されました | Raymond James | Strong Buy |
| 2020-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-11 | アップグレード | Wedbush | Underperform → Neutral |
| 2020-01-07 | 開始されました | SVB Leerink | Mkt Perform |
| 2019-12-19 | 開始されました | BofA/Merrill | Buy |
| 2019-11-22 | 開始されました | Wedbush | Underperform |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-08-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-07-30 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-04-12 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges - MSN
Jump Financial LLC Buys 293,075 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Technical Reactions to APLS Trends in Macro Strategies - news.stocktradersdaily.com
Marshall Wace LLP Buys 2,681,263 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Norges Bank Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 6.2%Still a Buy? - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Hold" by Analysts - MarketBeat
Apellis Pharmaceuticals (APLS): Valuation Check After Positive EMPAVELI Kidney Data and New FDA Approval - Yahoo Finance
Schroder Investment Management Group Grows Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
What downside risks could hit Apellis Pharmaceuticals Inc. (1JK) stockRecession Risk & AI Optimized Trade Strategies - Newser
Why millennials buy Apellis Pharmaceuticals Inc. (1JK) stockPrice Action & High Accuracy Trade Alerts - Newser
Prudential Financial Inc. Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Will Apellis Pharmaceuticals Inc. (1JK) stock issue positive guidanceJobs Report & Fast Entry Momentum Trade Alerts - Newser
Why Apellis Pharmaceuticals Inc. (1JK) stock gets analyst attentionRate Cut & High Conviction Buy Zone Picks - Newser
Apellis’ EMPAVELI shows 68% reduction in proteinuria for rare kidney diseases - Investing.com Nigeria
Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli - marketscreener.com
Apellis (APLS) Gains Boost from Positive Phase 3 Study Results - GuruFocus
Apellis Pharmaceuticals Announces Positive Phase 3 VALIANT Study Results for EMPAVELI in Treating C3 Glomerulopathy and Primary IC-MPGN - Quiver Quantitative
Transcript : Apellis Pharmaceuticals, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 02 - marketscreener.com
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally stronglyMarket Performance Summary & AI Powered Market Entry Ideas - Newser
Why Apellis Pharmaceuticals Inc. (1JK) stock could be top winnerJuly 2025 Summary & High Yield Equity Trading Tips - Newser
38,572 Shares in Apellis Pharmaceuticals, Inc. $APLS Purchased by Wealthedge Investment Advisors LLC - MarketBeat
Will Apellis Pharmaceuticals Inc. stock deliver long term returnsAnalyst Upgrade & Growth Oriented Trading Recommendations - Newser
Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight - GlobeNewswire Inc.
Virtus Investment Advisers LLC Acquires 12,106 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Steward Partners Investment Advisory LLC Buys 18,800 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy - MSN
Geode Capital Management LLC Raises Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Breakout Watch: How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peers2025 Valuation Update & Weekly Sector Rotation Insights - BỘ NỘI VỤ
Apellis Pharmaceuticals, Inc. $APLS Position Increased by Rhenman & Partners Asset Management AB - MarketBeat
Apellis Pharmaceuticals (APLS) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Trading the Move, Not the Narrative: (APLS) Edition - news.stocktradersdaily.com
Can Sanmitra Commercial Limited Maintain Its Strong Profit MarginsInterest Rate Changes & High Yield Investment Portfolio - earlytimes.in
Apellis Pharmaceuticals, Inc. $APLS Stock Position Decreased by SG Americas Securities LLC - MarketBeat
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Apellis Pharmaceuticals (Nasdaq: APLS) to Webcast Investor Chats at 2025 Conferences - Stock Titan
Apellis targets 225 EMPAVELI start forms by year-end amid steady SYFOVRE growth and expanded rare kidney launch - MSN
9 Oversold Biotech Stocks to Invest In - Insider Monkey
FY2025 Earnings Estimate for APLS Issued By Zacks Research - MarketBeat
Can Apellis Pharmaceuticals Inc. stock beat analyst upgradesShare Buyback & AI Powered Market Entry Ideas - newser.com
Will Apellis Pharmaceuticals Inc. stock deliver better than expected guidanceQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueQuarterly Investment Review & Safe Entry Momentum Tips - newser.com
Apellis Pharmaceuticals Faces Weak Start with 17.3% Gap Down Amid Market Concerns - Markets Mojo
Why Apellis Pharmaceuticals Inc. (1JK) stock stays on buy listsShare Buyback & Safe Swing Trade Setups - newser.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - 富途牛牛
Using AI based signals to follow Apellis Pharmaceuticals Inc.Gold Moves & Free Safe Entry Trade Signal Reports - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekPortfolio Value Report & Stepwise Trade Execution Plans - newser.com
Apellis Pharmaceuticals Inc (APLS) 財務データ
収益
当期純利益
現金流量
EPS
0.45%
0.12%
大文字化:
|
ボリューム (24 時間):